The creation of retatrutide, a novel dual activator targeting both GLP-1 and GIP receptors, involves a complex several-stage synthetic process. Initial routes focused on peptide fragment coupling, utilizing solid-phase production methodologies to build the long peptide sequence. Subsequent research has explored various approaches, including enzymat